LENZ Therapeutics, Inc. (NASDAQ:LENZ) counted 137 institutional investors among its 13F-reported shareholders for the quarter ended September 30, 2026.
These investors held 95.21% of LENZ Therapeutics' outstanding shares at the end of Q3 2026.
Total holdings of LENZ Therapeutics shares fell 13.85% from Q2 2026, and the number of holders fell 16.46% from Q3 2025.
Of these 137 holders, 70 added to their positions, 38 reduced their stakes and 29 left their positions unchanged.
Altogether, institutional holders owned 29.92Mn LENZ shares at the end of Q3 2026, down 4.81Mn from the prior quarter and up 796.6K from a year earlier.
Ra Capital Management, L.P. held the largest position in LENZ at 4.18Mn shares as of September 30, 2026, or 13.30% of shares outstanding.
The largest position increases in LENZ for Q3 2026 were by BlackRock, Inc. (+1.15Mn shares), Two Sigma Investments, LP (+429K shares), Acadian Asset Management LLC (+302.42K shares), Affinity Asset Advisors, LLC (+200K shares) and Goldman Sachs Group Inc (+198.25K shares).
Holders that trimmed the most shares of LENZ Therapeutics in Q3 2026 while keeping a position were FMR LLC (-2.95Mn shares), Squarepoint Ops LLC (-780.18K shares), Millennium Management LLC (-348.49K shares), Citadel Advisors LLC (-267.9K shares) and Bank of America Corp (-215.87K shares).
Business Quant data shows the 10 biggest positions in LENZ Therapeutics as of Q3 2026 were held by Ra Capital Management, L.P. (4.18Mn shares), Alpha Wave Global, LP (3.61Mn shares), BlackRock, Inc. (3.44Mn shares), Versant Venture Management, LLC (2.66Mn shares), Millennium Management LLC (1.16Mn shares), Vanguard Capital Management LLC (1.1Mn shares), 72 Investment Holdings, LLC (1.02Mn shares), Squarepoint Ops LLC (966.92K shares), Blue Owl Capital Holdings LP (781.72K shares) and Two Sigma Investments, LP (714.59K shares).